Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14525183 | 0.80 | EPHX1 (0.42) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL13062152 | 0.80 | EPHX1 (0.42) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL23838563 | 0.79 | — | — | |
| SCHEMBL18756769 | 0.75 | LMNA (0.32) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL18400698 | 0.74 | OPRM1 (0.31) | — | |
| SCHEMBL8852181 | 0.73 | — | — | |
| SCHEMBL21936360 | 0.73 | EPHX1 (0.46) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL12855699 | 0.72 | — | — | |
| SCHEMBL3071603 | 0.72 | — | — | |
| SCHEMBL7936451 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988123-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Janssen Pharmaceutica NV (BE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2018081367-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |